{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T17:04:07Z","timestamp":1794330247873,"version":"4.9.0"},"reference-count":180,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T00:00:00Z","timestamp":1749168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The B cell-activating factor (BAFF) system, comprising two ligands and three receptors, plays a pivotal role in adaptive and innate immunity, driving autoimmunity through dysregulated B and T cell survival, differentiation, and cytokine production. This review synthesizes evidence linking BAFF system overexpression to multiple autoimmune diseases, including systemic lupus erythematosus (SLE), Sj\u00f6gren\u2019s syndrome (SS), bullous pemphigoid (BP), pemphigus vulgaris (PV), and alopecia areata (AA), where elevated BAFF system molecule levels correlate with autoantibody titers, disease activity, and post-B cell depletion relapse. BAFF-targeted therapies have demonstrated efficacy in reducing disease activity in SLE and SS. Key challenges include interspecies receptor expression discrepancies and context-dependent signalling cascades. Emerging strategies, such as sequential therapy with rituximab followed by belimumab, show promise in treating refractory autoimmune diseases such as BP and PV by counteracting the post-depletion BAFF surge. Despite progress, mechanistic gaps in BAFF-mediated crosstalk between innate and adaptive immunity, as well as interspecies-specific pathogenesis warrant further investigation using humanized disease models and single-cell transcriptomic profiling. This review underscores the therapeutic potential of BAFF system modulation while advocating for disease-specific clinical trials to optimize precision-therapeutic targeting in autoimmune diseases.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1538555","type":"journal-article","created":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T01:22:23Z","timestamp":1749172943000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":36,"title":["The role of B cell-activating factor system in autoimmune diseases: mechanisms, disease implications, and therapeutic advances"],"prefix":"10.3389","volume":"16","author":[{"given":"Liang","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengxian","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erle","family":"Dang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjiang","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/nri2572","article-title":"Cracking the BAFF code","volume":"9","author":"Mackay","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/nri844","article-title":"BAFF: a fundamental survival factor for B cells","volume":"2","author":"Mackay","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"108796","DOI":"10.1016\/j.biopha.2019.108796","article-title":"BAFF promotes T cell activation through the BAFF-BAFF-R-PI3K-Akt signaling pathway","volume":"114","author":"Hu","year":"2019","journal-title":"BioMed Pharmacother"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2013.12.011","article-title":"The function of BAFF on T helper cells in autoimmunity","volume":"25","author":"Chen","year":"2014","journal-title":"Cytokine Growth Factor Rev"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2006.04.005","article-title":"The role of the BAFF\/APRIL system on T cell function","volume":"18","author":"Mackay","year":"2006","journal-title":"Semin Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-12-017319","article-title":"A role for BLyS in the activation of innate immune cells","volume":"108","author":"Chang","year":"2006","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.180.11.7394","article-title":"B lymphocyte stimulator regulates adaptive immune responses by directly promoting dendritic cell maturation","volume":"180","author":"Chang","year":"2008","journal-title":"J Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/imcb.v100.10","article-title":"The effects of B-cell-activating factor on the population size, maturation and function of murine natural killer cells","volume":"100","author":"Quah","year":"2022","journal-title":"Immunol Cell Biol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2013.04.003","article-title":"The BAFF\/APRIL system: emerging functions beyond B cell biology and autoimmunity","volume":"24","author":"Vincent","year":"2013","journal-title":"Cytokine Growth Factor Rev"},{"key":"B10","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.cytogfr.2021.11.004","article-title":"B cell-activating factor and its targeted therapy in autoimmune diseases","volume":"64","author":"Zhang","year":"2022","journal-title":"Cytokine Growth Factor Rev"},{"key":"B11","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jdermsci.2006.12.008","article-title":"Increased serum levels of a proliferation-inducing ligand in patients with bullous pemphigoid","volume":"46","author":"Watanabe","year":"2007","journal-title":"J Dermatol Sci"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.022491","article-title":"Raised serum APRIL levels in patients with systemic lupus erythematosus","volume":"64","author":"Koyama","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"B13","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1080\/08916934.2020.1736049","article-title":"Abnormal expression of BAFF and its receptors in peripheral blood and skin lesions from systemic lupus erythematosus patients","volume":"53","author":"Chen","year":"2020","journal-title":"Autoimmunity"},{"key":"B14","article-title":"Investigation of serum APRIL and BAFF levels in pemphigus vulgaris patients in Southern Iran","volume":"14","author":"Torkamani","year":"2011","journal-title":"Iran J Dermatol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2006.07305.x","article-title":"Serum levels of BAFF are increased in bullous pemphigoid but not in pemphigus vulgaris","volume":"155","author":"Asashima","year":"2006","journal-title":"Br J Dermatol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1002\/art.21526","article-title":"Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes","volume":"54","author":"Matsushita","year":"2006","journal-title":"Arthritis Rheum"},{"key":"B17","article-title":"Elevated serum APRIL levels in patients with systemic sclerosis: distinct profiles of systemic sclerosis categorized by APRIL and BAFF","volume":"34","author":"Matsushita","year":"2007","journal-title":"J Rheumatol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1172\/JCI0214121","article-title":"Association of BAFF\/BLyS overexpression and altered B cell differentiation with Sj\u00f6gren\u2019s syndrome","volume":"109","author":"Groom","year":"2002","journal-title":"J Clin Invest"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes080","article-title":"The expression of APRIL in Sjogren\u2019s syndrome: aberrant expression of APRIL in the salivary gland","volume":"51","author":"Vosters","year":"2012","journal-title":"Rheumatol (Oxford)"},{"key":"B20","doi-asserted-by":"publisher","first-page":"103339","DOI":"10.1016\/j.autrev.2023.103339","article-title":"Biomarkers in alopecia Areata: A systematic review and meta-analysis","volume":"22","author":"Zaaroura","year":"2023","journal-title":"Autoimmun Rev"},{"key":"B21","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1016\/S0140-6736(18)33074-5","article-title":"Belimumab in kidney transplantation","volume":"393","author":"Ahmed","year":"2019","journal-title":"Lancet"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/art.40358","article-title":"Belimumab for the treatment of early diffuse systemic sclerosis: results of a randomized, double-blind, placebo-controlled, pilot trial","volume":"70","author":"Gordon","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203991","article-title":"Efficacy and safety of belimumab in primary Sj\u00f6gren\u2019s syndrome: results of the BELISS open-label phase II study","volume":"74","author":"Mariette","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-020-00092-2","article-title":"B cell depletion therapies in autoimmune disease: advances and mechanistic insights","volume":"20","author":"Lee","year":"2021","journal-title":"Nat Rev Drug Discovery"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1126\/science.285.5425.260","article-title":"BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator","volume":"285","author":"Moore","year":"1999","journal-title":"Science"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1084\/jem.188.6.1185","article-title":"APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth","volume":"188","author":"Hahne","year":"1998","journal-title":"J Exp Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1182\/blood.V97.1.198","article-title":"Synthesis and release of B-lymphocyte stimulator from myeloid cells","volume":"97","author":"Nardelli","year":"2001","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201040591","article-title":"Mutation of the BAFF furin cleavage site impairs B-cell homeostasis and antibody responses","volume":"41","author":"Bossen","year":"2011","journal-title":"Eur J Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/S1359-6101(03)00023-6","article-title":"The TNF family members BAFF and APRIL: the growing complexity","volume":"14","author":"Mackay","year":"2003","journal-title":"Cytokine Growth Factor Rev"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxh043","article-title":"BAFF production by antigen-presenting cells provides T cell co-stimulation","volume":"16","author":"Huard","year":"2004","journal-title":"Int Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0901186","article-title":"Adipocytes as immune cells: differential expression of TWEAK, BAFF, and APRIL and their receptors (Fn14, BAFF-R, TACI, and BCMA) at different stages of normal and pathological adipose tissue development","volume":"183","author":"Alexaki","year":"2009","journal-title":"J Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.0412210","article-title":"Induction of BAFF expression by IFN-\u03b3 via JAK\/STAT signaling pathways in human intestinal epithelial cells","volume":"93","author":"Woo","year":"2013","journal-title":"J Leukoc Biol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1128\/CMR.00046-17","article-title":"The role of BAFF system molecules in host response to pathogens","volume":"30","author":"Sakai","year":"2017","journal-title":"Clin Microbiol Rev"},{"key":"B34","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nrrheum.2011.122","article-title":"Crosstalk in RA synovia-TLR3-BAFF axis sustains B-cell activation","volume":"7","author":"Leah","year":"2011","journal-title":"Nat Rev Rheumatol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.179.9.5947","article-title":"In vitro and in vivo activation induces BAFF and APRIL expression in B cells","volume":"179","author":"Chu","year":"2007","journal-title":"J Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1172\/JCI33760","article-title":"APRIL secreted by neutrophils binds to heparan sulfate proteoglycans to create plasma cell niches in human mucosa","volume":"118","author":"Huard","year":"2008","journal-title":"J Clin Invest"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15061791","article-title":"The BAFF-APRIL system in cancer","volume":"15","author":"Ullah","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1126\/science.1061965","article-title":"BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF","volume":"293","author":"Thompson","year":"2001","journal-title":"Science"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/35010115","article-title":"TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease","volume":"404","author":"Gross","year":"2000","journal-title":"Nature"},{"key":"B40","doi-asserted-by":"publisher","first-page":"7333","DOI":"10.1038\/ncomms8333","article-title":"\u03b3-Secretase directly sheds the survival receptor BCMA from plasma cells","volume":"6","author":"Laurent","year":"2015","journal-title":"Nat Commun"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1402070","article-title":"The immunoregulator soluble TACI is released by ADAM10 and reflects B cell activation in autoimmunity","volume":"194","author":"Hoffmann","year":"2015","journal-title":"J Immunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2018.07.002","article-title":"Shedding of BAFF\/APRIL receptors controls B cells","volume":"39","author":"Meinl","year":"2018","journal-title":"Trends Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1021\/bi048227k","article-title":"Selectivity of BAFF\/BLyS and APRIL for binding to the TNF family receptors BAFFR\/BR3 and BCMA","volume":"44","author":"Day","year":"2005","journal-title":"Biochemistry"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M005224200","article-title":"Tumor necrosis factor (TNF) receptor superfamily member TACI is a high affinity receptor for TNF family members APRIL and BLyS","volume":"275","author":"Wu","year":"2000","journal-title":"J Biol Chem"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2006.04.006","article-title":"BAFF, APRIL and their receptors: structure, function and signaling","volume":"18","author":"Bossen","year":"2006","journal-title":"Semin Immunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1080\/14728222.2020.1821647","article-title":"The BAFF\/APRIL system as therapeutic target in multiple sclerosis","volume":"24","author":"Magliozzi","year":"2020","journal-title":"Expert Opin Ther Targets"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.173.2.807","article-title":"B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells","volume":"173","author":"Ng","year":"2004","journal-title":"J Immunol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20100086","article-title":"Myeloid cells, BAFF, and IFN-gamma establish an inflammatory loop that exacerbates autoimmunity in Lyn-deficient mice","volume":"207","author":"Scapini","year":"2010","journal-title":"J Exp Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200425198","article-title":"BAFF binding to T cell-expressed BAFF-R costimulates T cell proliferation and alloresponses","volume":"34","author":"Ye","year":"2004","journal-title":"Eur J Immunol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"102736","DOI":"10.1016\/j.autrev.2020.102736","article-title":"B cell activating factor (BAFF): Structure, functions, autoimmunity and clinical implications in Systemic Lupus Erythematosus (SLE)","volume":"20","author":"M\u00f6ckel","year":"2021","journal-title":"Autoimmun Rev"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11051310","article-title":"Future treatment options in systemic sclerosis-potential targets and ongoing clinical trials","volume":"11","author":"Maciejewska","year":"2022","journal-title":"J Clin Med"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1127417","article-title":"Pathogenesis and treatment of Sjogren\u2019s syndrome: Review and update","volume":"14","author":"Zhan","year":"2023","journal-title":"Front Immunol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2010.00944.x","article-title":"B-cell stage and context-dependent requirements for survival signals from BAFF and the B-cell receptor","volume":"237","author":"Mackay","year":"2010","journal-title":"Immunol Rev"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02285","article-title":"BAFF and BAFF-receptor in B cell selection and survival","volume":"9","author":"Smulski","year":"2018","journal-title":"Front Immunol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.170.12.5820","article-title":"Cutting edge: B cell receptor signals regulate BLyS receptor levels in mature B cells and their immediate progenitors","volume":"170","author":"Smith","year":"2003","journal-title":"J Immunol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2005.08.005","article-title":"BAFF-R, the major B cell-activating factor receptor, is expressed on most mature B cells and B-cell lymphoproliferative disorders","volume":"36","author":"Rodig","year":"2005","journal-title":"Hum Pathol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.168.12.5993","article-title":"Cutting edge: BLyS enables survival of transitional and mature B cells through distinct mediators","volume":"168","author":"Hsu","year":"2002","journal-title":"J Immunol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1001120","article-title":"The structure of the TNFRSF13C promoter enables differential expression of BAFF-R during B cell ontogeny and terminal differentiation","volume":"185","author":"Mihalcik","year":"2010","journal-title":"J Immunol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20031330","article-title":"BCMA is essential for the survival of long-lived bone marrow plasma cells","volume":"199","author":"O'Connor","year":"2004","journal-title":"J Exp Med"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1172\/JCI18025","article-title":"BAFF selectively enhances the survival of plasmablasts generated from human memory B cells","volume":"112","author":"Avery","year":"2003","journal-title":"J Clin Invest"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-08-2673","article-title":"Gene expression profiling reveals a highly specialized genetic program of plasma cells","volume":"101","author":"Underhill","year":"2003","journal-title":"Blood"},{"key":"B62","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1182\/blood-2002-10-3161","article-title":"Gene expression profiling of plasma cells and plasmablasts: toward a better understanding of the late stages of B-cell differentiation","volume":"102","author":"Tarte","year":"2003","journal-title":"Blood"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2527","article-title":"Mcl-1 is essential for the survival of plasma cells","volume":"14","author":"Peperzak","year":"2013","journal-title":"Nat Immunol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M115.661405","article-title":"Stoichiometry of heteromeric BAFF and APRIL cytokines dictates their receptor binding and signaling properties","volume":"290","author":"Schuepbach-Mallepell","year":"2015","journal-title":"J Biol Chem"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.179.4.2282","article-title":"TACI is required for efficient plasma cell differentiation in response to T-independent type 2 antigens","volume":"179","author":"Mantchev","year":"2007","journal-title":"J Immunol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/j.jaci.2009.03.019","article-title":"Transmembrane activator, calcium modulator, and cyclophilin ligand interactor drives plasma cell differentiation in LPS-activated B cells","volume":"123","author":"Ozcan","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-05-353961","article-title":"TACI deficiency impairs sustained Blimp-1 expression in B cells decreasing long-lived plasma cells in the bone marrow","volume":"118","author":"Tsuji","year":"2011","journal-title":"Blood"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1006\/jmbi.2001.5296","article-title":"Crystal structure of extracellular human BAFF, a TNF family member that stimulates B lymphocytes","volume":"315","author":"Karpusas","year":"2002","journal-title":"J Mol Biol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1084\/jem.190.11.1697","article-title":"Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations","volume":"190","author":"Mackay","year":"1999","journal-title":"J Exp Med"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1084\/jem.189.11.1747","article-title":"BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth","volume":"189","author":"Schneider","year":"1999","journal-title":"J Exp Med"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20030789","article-title":"Normal B cell homeostasis requires B cell activation factor production by radiation-resistant cells","volume":"198","author":"Gorelik","year":"2003","journal-title":"J Exp Med"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20030495","article-title":"Normal induction but attenuated progression of germinal center responses in BAFF and BAFF-R signaling-deficient mice","volume":"198","author":"Rahman","year":"2003","journal-title":"J Exp Med"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1172\/JCI0215034","article-title":"APRIL modulates B and T cell immunity","volume":"109","author":"Stein","year":"2002","journal-title":"J Clin Invest"},{"key":"B74","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1128\/MCB.24.3.997-1006.2004","article-title":"APRIL-deficient mice have normal immune system development","volume":"24","author":"Varfolomeev","year":"2004","journal-title":"Mol Cell Biol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0307348101","article-title":"Impaired IgA class switching in APRIL-deficient mice","volume":"101","author":"Castigli","year":"2004","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2008.04.006","article-title":"TACI, an enigmatic BAFF\/APRIL receptor, with new unappreciated biochemical and biological properties","volume":"19","author":"Mackay","year":"2008","journal-title":"Cytokine Growth Factor Rev"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1038\/89790","article-title":"Activation and accumulation of B cells in TACI-deficient mice","volume":"2","author":"Yan","year":"2001","journal-title":"Nat Immunol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1016\/S1471-4906(01)02159-7","article-title":"The role of BAFF in B-cell maturation, T-cell activation and autoimmunity","volume":"23","author":"Mackay","year":"2002","journal-title":"Trends Immunol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.167.11.6225","article-title":"T cell costimulation by the TNF ligand BAFF","volume":"167","author":"Huard","year":"2001","journal-title":"J Immunol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/S1074-7613(01)00183-2","article-title":"TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. impaired B cell maturation in mice lacking BLyS","volume":"15","author":"Gross","year":"2001","journal-title":"Immunity"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2018.11.008","article-title":"BAFF-R and TACI expression on CD3+ T cells: Interplay among BAFF, APRIL and T helper cytokines profile in systemic lupus erythematosus","volume":"114","author":"Salazar-Camarena","year":"2019","journal-title":"Cytokine"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000209","article-title":"Blockade of BAFF receptor BR3 on T cells enhances their activation and cytotoxicity","volume":"41","author":"Bloom","year":"2018","journal-title":"J Immunother"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0806044105","article-title":"Local BAFF gene silencing suppresses Th17-cell generation and ameliorates autoimmune arthritis","volume":"105","author":"Lai Kwan Lam","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1300749","article-title":"IL-4 regulates Bim expression and promotes B cell maturation in synergy with BAFF conferring resistance to cell death at negative selection checkpoints","volume":"192","author":"Granato","year":"2014","journal-title":"J Immunol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.175.9.6163","article-title":"A role for B cell-activating factor of the TNF family in chemically induced autoimmunity","volume":"175","author":"Zheng","year":"2005","journal-title":"J Immunol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.995149","article-title":"BAFF blockade attenuates acute graft-versus-host disease directly via the dual regulation of T- and B-cell homeostasis","volume":"13","author":"Jeon","year":"2022","journal-title":"Front Immunol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1105774108","article-title":"Noncanonical NF-kappaB regulates inducible costimulator (ICOS) ligand expression and T follicular helper cell development","volume":"108","author":"Hu","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1200386109","article-title":"Deficiency in TNFRSF13B (TACI) expands T-follicular helper and germinal center B cells via increased ICOS-ligand expression but impairs plasma cell survival","volume":"109","author":"Ou","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1421580112","article-title":"TACI deficiency leads to alternatively activated macrophage phenotype and susceptibility to Leishmania infection","volume":"112","author":"Allman","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B90","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.imlet.2008.07.005","article-title":"hsBAFF enhances activity of NK cells by regulation of CD4(+) T lymphocyte function","volume":"120","author":"Zhang","year":"2008","journal-title":"Immunol Lett"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1177\/09612033211028653","article-title":"10 Years of belimumab experience: What have we learnt","volume":"30","author":"Levy","year":"2021","journal-title":"Lupus"},{"key":"B92","doi-asserted-by":"publisher","first-page":"6","DOI":"10.4049\/jimmunol.166.1.6","article-title":"Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus","volume":"166","author":"Zhang","year":"2001","journal-title":"J Immunol"},{"key":"B93","doi-asserted-by":"publisher","first-page":"103262","DOI":"10.1016\/j.autrev.2022.103262","article-title":"Circulating and skin biopsy-present cytokines related to the pathogenesis of cutaneous lupus erythematosus","volume":"22","author":"Erazo-Mart\u00ednez","year":"2023","journal-title":"Autoimmun Rev"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1111\/exd.2018.27.issue-1","article-title":"High expression of B lymphocyte stimulator in lesional keratinocytes of patients with cutaneous lupus erythematosus","volume":"27","author":"Wenzel","year":"2018","journal-title":"Exp Dermatol"},{"key":"B95","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/modpathol.2010.184","article-title":"Intrarenal production of B-cell survival factors in human lupus nephritis","volume":"24","author":"Neusser","year":"2011","journal-title":"Mod Pathol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12894","article-title":"Urinary B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL): potential biomarkers of active lupus nephritis","volume":"187","author":"Phatak","year":"2017","journal-title":"Clin Exp Immunol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker016","article-title":"Absence of up-regulation for a proliferation-inducing ligand in Sj\u00f6gren\u2019s sialadenitis lesions","volume":"50","author":"Lombardi","year":"2011","journal-title":"Rheumatol (Oxford)"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1002\/art.22458","article-title":"Aberrant expression of BAFF by B lymphocytes infiltrating the salivary glands of patients with primary Sj\u00f6gren\u2019s syndrome","volume":"56","author":"Daridon","year":"2007","journal-title":"Arthritis Rheum"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1111\/apl.2013.16.issue-2","article-title":"Serum B-cell activating factor assessment in a population of Egyptian patients with systemic sclerosis","volume":"16","author":"Abdo","year":"2013","journal-title":"Int J Rheum Dis"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23126777","article-title":"Ligation of TLR homologue CD180 of B cells activates the PI3K\/Akt\/mTOR pathway in systemic sclerosis and induces a pathological shift in the expression of BAFF receptors","volume":"23","author":"Erd\u0151-Bony\u00e1r","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.666022","article-title":"Modifications of the BAFF\/BAFF-receptor axis in patients with pemphigus treated with rituximab versus standard corticosteroid regimen","volume":"12","author":"Hebert","year":"2021","journal-title":"Front Immunol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2008.01.004","article-title":"Serum BAFF and APRIL levels in patients with alopecia areata","volume":"50","author":"Kuwano","year":"2008","journal-title":"J Dermatol Sci"},{"key":"B103","doi-asserted-by":"publisher","first-page":"928030","DOI":"10.1155\/2010\/928030","article-title":"Cytokines and other mediators in alopecia areata","volume":"2010","author":"Gregoriou","year":"2010","journal-title":"Mediators Inflammation"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-016-1617-z","article-title":"B cell activating factor and T-helper 17 cells: possible synergistic culprits in the pathogenesis of Alopecia Areata","volume":"308","author":"Elela","year":"2016","journal-title":"Arch Dermatol Res"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-101921-042422","article-title":"Systemic lupus erythematosus pathogenesis: interferon and beyond","volume":"41","author":"Caielli","year":"2023","journal-title":"Annu Rev Immunol"},{"key":"B106","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s12016-017-8627-2","article-title":"The cutaneous spectrum of lupus erythematosus","volume":"53","author":"Ribero","year":"2017","journal-title":"Clin Rev Allergy Immunol"},{"key":"B107","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1136\/ard.2008.090928","article-title":"Serum levels of tumour necrosis factor family members a proliferation-inducing ligand (APRIL) and B lymphocyte stimulator (BLyS) are inversely correlated in systemic lupus erythematosus","volume":"68","author":"Morel","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2009.12.012","article-title":"Raised serum level of APRIL in patients with systemic lupus erythematosus: correlations with disease activity indices","volume":"135","author":"Hegazy","year":"2010","journal-title":"Clin Immunol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1002\/art.23678","article-title":"Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus","volume":"58","author":"Petri","year":"2008","journal-title":"Arthritis Rheum"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket120","article-title":"Elevated B lymphocyte stimulator levels are associated with increased damage in an Irish systemic lupus erythematosus cohort","volume":"52","author":"McCarthy","year":"2013","journal-title":"Rheumatol (Oxford)"},{"key":"B111","article-title":"BLyS levels in sera of patients with systemic lupus erythematosus: clinical and serological correlation","volume":"16","author":"Elbirt","year":"2014","journal-title":"Isr Med Assoc J"},{"key":"B112","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1111\/cei.12975","article-title":"Associations of B cell-activating factor (BAFF) and anti-BAFF autoantibodies with disease activity in multi-ethnic Asian systemic lupus erythematosus patients in Singapore","volume":"189","author":"Howe","year":"2017","journal-title":"Clin Exp Immunol"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1111\/j.1582-4934.2009.00817.x","article-title":"Blockade of B-cell-activating factor suppresses lupus-like syndrome in autoimmune BXSB mice","volume":"14","author":"Ding","year":"2010","journal-title":"J Cell Mol Med"},{"key":"B114","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.cellimm.2009.10.004","article-title":"BAFF overexpression promotes anti-dsDNA B-cell maturation and antibody secretion","volume":"261","author":"Thorn","year":"2010","journal-title":"Cell Immunol"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2014.33","article-title":"The BAFF\/APRIL system in SLE pathogenesis","volume":"10","author":"Vincent","year":"2014","journal-title":"Nat Rev Rheumatol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1177\/0961203317717083","article-title":"Renal tubular epithelial cell-derived BAFF expression mediates kidney damage and correlates with activity of proliferative lupus nephritis in mouse and men","volume":"27","author":"Schwarting","year":"2018","journal-title":"Lupus"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1600281","article-title":"BAFF Induces Tertiary Lymphoid Structures and Positions T Cells within the Glomeruli during Lupus Nephritis","volume":"198","author":"Kang","year":"2017","journal-title":"J Immunol"},{"key":"B118","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdermsci.2013.11.007","article-title":"Differential expression of BAFF and its receptors in discoid lupus erythematosus patients","volume-title":"J Dermatol Sci","author":"Chong","year":"2014"},{"key":"B119","doi-asserted-by":"publisher","first-page":"16047","DOI":"10.1038\/nrdp.2016.47","article-title":"Sjogren syndrome","volume":"2","author":"Brito-Zeron","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1136\/ard.62.2.168","article-title":"The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sj\u00f6gren\u2019s syndrome","volume":"62","author":"Mariette","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"B121","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.clim.2016.01.015","article-title":"Early BAFF receptor blockade mitigates murine Sjogren\u2019s syndrome: Concomitant targeting of CXCL13 and the BAFF receptor prevents salivary hypofunction","volume":"164","author":"Sharma","year":"2016","journal-title":"Clin Immunol"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2014.02.004","article-title":"Specific forms of BAFF favor BAFF receptor-mediated epithelial cell survival","volume":"51","author":"Lahiri","year":"2014","journal-title":"J Autoimmun"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0803588","article-title":"Ectopic germinal centers are rare in Sjogren\u2019s syndrome salivary glands and do not exclude autoreactive B cells","volume":"182","author":"Le Pottier","year":"2009","journal-title":"J Immunol"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2010.05.006","article-title":"B-cell tolerance breakdown in Sj\u00f6gren\u2019s syndrome: focus on BAFF","volume":"9","author":"Varin","year":"2010","journal-title":"Autoimmun Rev"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-020-00637-0","article-title":"Expression of BAFF and BAFF receptors in primary Sj\u00f6gren\u2019s syndrome patients with ectopic germinal center-like structures","volume":"20","author":"Carrillo-Ballesteros","year":"2020","journal-title":"Clin Exp Med"},{"key":"B126","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.clim.2016.06.007","article-title":"BAFF overexpression increases lymphocytic infiltration in Sj\u00f6gren\u2019s target tissue, but only inefficiently promotes ectopic B-cell differentiation","volume":"169","author":"Ding","year":"2016","journal-title":"Clin Immunol"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01692-0","article-title":"Systemic sclerosis","volume":"401","author":"Volkmann","year":"2023","journal-title":"Lancet"},{"key":"B128","doi-asserted-by":"publisher","first-page":"R168","DOI":"10.1186\/ar4352","article-title":"B lymphocytes and B-cell activating factor promote collagen and profibrotic markers expression by dermal fibroblasts in systemic sclerosis","volume":"15","author":"Fran\u00e7ois","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jid.5700919","article-title":"BAFF antagonist attenuates the development of skin fibrosis in tight-skin mice","volume":"127","author":"Matsushita","year":"2007","journal-title":"J Invest Dermatol"},{"key":"B130","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaut.2014.08.003","article-title":"B cell activating factor is central to bleomycin- and IL-17-mediated experimental pulmonary fibrosis","volume":"56","author":"Francois","year":"2015","journal-title":"J Autoimmun"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61140-4","article-title":"Pemphigoid diseases","volume":"381","author":"Schmidt","year":"2013","journal-title":"Lancet"},{"key":"B132","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1111\/exd.2014.23.issue-8","article-title":"B-cell activating factor detected on both naive and memory B cells in bullous pemphigoid","volume":"23","author":"Qian","year":"2014","journal-title":"Exp Dermatol"},{"key":"B133","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1111\/j.1600-0625.2006.00485.x","article-title":"Elevated serum BAFF levels in patients with localized scleroderma in contrast to other organ-specific autoimmune diseases","volume":"16","author":"Matsushita","year":"2007","journal-title":"Exp Dermatol"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2013.236","article-title":"Association of serum B-cell activating factor level and proportion of memory and transitional B cells with clinical response after rituximab treatment of bullous pemphigoid patients","volume":"133","author":"Hall","year":"2013","journal-title":"J Invest Dermatol"},{"key":"B135","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.jid.2022.07.006","article-title":"Dipeptidyl peptidase 4 inhibitor\u2013Associated bullous pemphigoid is characterized by an altered expression of cytokines in the skin","volume":"143","author":"Tuusa","year":"2023","journal-title":"J Invest Dermatol"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31778-7","article-title":"Pemphigus","volume":"394","author":"Schmidt","year":"2019","journal-title":"Lancet"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.16363","article-title":"Elevated serum level of B-cell activating factor (BAFF) after rituximab therapy in pemphigus vulgaris patients suggests a possible therapeutic efficacy of B-cell depletion therapies combined with anti-BAFF agents","volume":"62","author":"Daneshvar","year":"2023","journal-title":"Int J Dermatol"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2009.27","article-title":"Rituximab mediates a strong elevation of B-cell-activating factor associated with increased pathogen-specific IgG but not autoantibodies in pemphigus vulgaris","volume":"129","author":"Nagel","year":"2009","journal-title":"J Invest Dermatol"},{"key":"B139","doi-asserted-by":"publisher","first-page":"R109","DOI":"10.1186\/ar2506","article-title":"Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus","volume":"10","author":"Furie","year":"2008","journal-title":"Arthritis Res Ther"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1002\/art.24699","article-title":"A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus","volume":"61","author":"Wallace","year":"2009","journal-title":"Arthritis Rheum"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1002\/art.30613","article-title":"A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus","volume":"63","author":"Furie","year":"2011","journal-title":"Arthritis Rheum"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1002\/art.2018.70.issue-8","article-title":"Efficacy and safety of subcutaneous belimumab in anti-double-stranded DNA-positive, hypocomplementemic patients with systemic lupus erythematosus","volume":"70","author":"Doria","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1002\/art.40049","article-title":"Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: A fifty-two-week randomized, double-blind, placebo-controlled study","volume":"69","author":"Stohl","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1002\/art.40439","article-title":"Long-term safety and efficacy of belimumab in patients with systemic lupus erythematosus: A continuation of a seventy-six-week phase III parent study in the United States","volume":"70","author":"Furie","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2001180","article-title":"Two-year, randomized, controlled trial of belimumab in lupus nephritis","volume":"383","author":"Furie","year":"2020","journal-title":"N Engl J Med"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev257","article-title":"Efficacy and safety of belimumab given for 12 months in primary Sj\u00f6gren\u2019s syndrome: the BELISS open-label phase II study","volume":"54","author":"De Vita","year":"2015","journal-title":"Rheumatol (Oxford)"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214720","article-title":"Treatment of primary Sj\u00f6gren\u2019s syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity","volume":"78","author":"D\u00f6rner","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02251-0","article-title":"Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sj\u00f6gren\u2019s syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial","volume":"399","author":"Bowman","year":"2022","journal-title":"Lancet"},{"key":"B150","unstructured":"Two-arm study to assess efficacy and safety of Ianalumab (VAY736) in patients with active Sjogren\u2019s syndrome (NEPTUNUS-1)"},{"key":"B151","unstructured":"Three-arm study to assess efficacy and safety of Ianalumab (VAY736) in patients with active Sjogren\u2019s syndrome (NEPTUNUS-2)"},{"key":"B152","unstructured":"Study of efficacy and safety of VAY736 in patients with pemphigus vulgaris"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-205067","article-title":"Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial)","volume":"74","author":"Isenberg","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1002\/art.39809","article-title":"Post hoc analysis of the phase II\/III APRIL-SLE study: association between response to atacicept and serum biomarkers including BLyS and APRIL","volume":"69","author":"Gordon","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"B155","unstructured":"Efficacy and safety of atacicept in systemic lupus erythematosus (ADDRESS II)"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1002\/art.40360","article-title":"Efficacy and safety of atacicept in patients with systemic lupus erythematosus: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled, parallel-arm, phase IIb study","volume":"70","author":"Merrill","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"B157","unstructured":"Long-term safety and tolerability of atacicept (Long-term Follow-Up of Participant Who Participated in ADDRESS II)"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab115","article-title":"Safety and clinical activity of atacicept in the long-term extension of the phase 2b ADDRESS II study in systemic lupus erythematosus","volume":"60","author":"Wallace","year":"2021","journal-title":"Rheumatol (Oxford)"},{"key":"B159","unstructured":"Atacicept in subjects with active lupus nephritis (COMPASS) (COMPASS)"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-020-08820-7","article-title":"B cell aberrance in lupus: the ringleader and the solution","volume":"62","author":"Nie","year":"2022","journal-title":"Clin Rev Allergy Immunol"},{"key":"B161","unstructured":"Study of RC18 administered subcutaneously to subjects with Systemic Lupus Erythematosus(SLE)"},{"key":"B162","unstructured":"Study of recombinant human B lymphocyte(RC18) administered subcutaneously to subjects with Systemic Lupus Erythematosus(SLE)"},{"key":"B163","unstructured":"A study of telitacicept for the treatment of moderately to severely active systemic lupus erythematosus"},{"key":"B164","unstructured":"A study of TACI-antibody fusion protein injection (RC18) in subjects with primary Sj\u00f6gren\u2019s syndrome"},{"key":"B165","unstructured":"A study to evaluate the efficacy and safety of telitacicept in subjects with active primary Sjogren\u2019s syndrome"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1002\/art.41466","article-title":"Phase II randomized trial of rituximab plus cyclophosphamide followed by belimumab for the treatment of lupus nephritis","volume":"73","author":"Atisha-Fregoso","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-025687","article-title":"Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol","volume":"9","author":"Teng","year":"2019","journal-title":"BMJ Open"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-225686","article-title":"Efficacy and safety of sequential therapy with subcutaneous belimumab and one cycle of rituximab in patients with systemic lupus erythematosus: the phase 3, randomised, placebo-controlled BLISS-BELIEVE study","volume":"83","author":"Aranow","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B169","unstructured":"Synergetic B-cell immunomodulation in SLE - 2nd study. (SynBioSe-2)"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.163030","article-title":"A randomized, phase II study of sequential belimumab and rituximab in primary Sj\u00f6gren\u2019s syndrome","volume":"7","author":"Mariette","year":"2022","journal-title":"JCI Insight"},{"key":"B171","unstructured":"Belimumab and Rituximab combination therapy for the treatment of diffuse cutaneous systemic sclerosis"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.553075","article-title":"Rituximab followed by belimumab controls severe lupus nephritis and bullous pemphigoid in systemic lupus erythematosus refractory to several combination therapies","volume":"7","author":"Petricca","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15621","article-title":"Belimumab for the treatment of pemphigus","volume":"35","author":"Ruan","year":"2022","journal-title":"Dermatol Ther"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-020-00544-w","article-title":"Novel therapies for pemphigus vulgaris","volume":"21","author":"Altman","year":"2020","journal-title":"Am J Clin Dermatol"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(14)70028-6","article-title":"Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial","volume":"13","author":"Kappos","year":"2014","journal-title":"Lancet Neurol"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01591-1","article-title":"Telitacicept: first approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"key":"B177","unstructured":"A study to evaluate the efficacy and safety of telitacicept in subjects with active primary Sjogren\u2019s syndrome"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.060772","article-title":"Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production","volume":"66","author":"Lavie","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2004.05.010","article-title":"Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches","volume":"20","author":"Thien","year":"2004","journal-title":"Immunity"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.7326\/M21-2078","article-title":"Effectiveness of belimumab after rituximab in systemic lupus erythematosus: A randomized controlled trial","volume":"174","author":"Shipa","year":"2021","journal-title":"Ann Intern Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1538555\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T01:22:27Z","timestamp":1749172947000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1538555\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,6]]},"references-count":180,"alternative-id":["10.3389\/fimmu.2025.1538555"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1538555","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,6]]},"article-number":"1538555"}}